# MED earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/MED) · [Earnings tab](https://www.lopjlb.com/stock/MED?tab=earnings) Updated: 2026-10-26T03:03:23 Quarters analyzed: 8 ## Cross-quarter narrative Across the eight earnings CallCards, Medifast’s revenue trajectory has deepened from a 38% YoY drop in Q4 2024 to consistent double‑digit declines through Q4 2025 and into 2026, while gross margins have eroded modestly as fixed‑cost leverage wanes. Coach attrition remains a persistent headwind, with active earning coaches falling 34% YoY in Q4 2024 and a cumulative 40%+ decline by Q4 2025, though Q4 2026 notes a tentative reversal in productivity. The company has shifted from cost‑intensive company‑led marketing toward coach‑driven acquisition, launching Premier+ pricing and EDGE incentives to improve efficiency. Product development has progressed: the ASCEND line launched in Q4 2024, ACTIVE followed in early 2025, and a broader metabolic‑health portfolio—including the Trilivy brand and a Metabolic Health Institute—was introduced in 2026. Cost‑reduction programs such as Fuel for the Future and the Catalyst initiative aim to restore profitability, yet margin pressure persists. External risk from rapid GLP‑1 adoption is repeatedly flagged, influencing both demand and the strategic pivot toward metabolic‑health solutions. Cash remains strong with no debt, providing flexibility for ongoing restructuring and product rollout, though execution risk around new launches and tax‑asset allowances adds uncertainty. ## Latest CallCard · Q2 Medifast reports Q2 revenue in line with guidance, coach productivity up but active coach count down sharply, and highlights new Trilivy brand and Catalyst cost‑savings program as paths to Q4 profitability. **Guidance:** maintained — Guidance for Q3 revenue $60‑80M and full‑year revenue $270‑300M was unchanged. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted positive coach productivity, new brand launch, and confidence in returning to profitability. ### Demand visibility Demand appears stable with coach productivity gains offsetting coach count decline. Management cites high public concern about metabolic health, strong coach engagement at the July convention, and continued GLP‑1 adoption affecting coach numbers. ### Margins / costs Margins pressured by loss of leverage and lower volumes, but expected to improve as top line stabilizes and Catalyst delivers savings. Q2 gross margin fell to 69.9% from 72.6% YoY; SG&A as % of revenue rose 200 bps due to fixed‑cost leverage loss and Trilivy launch, while Catalyst aims to restore margin leverage. ### Capital allocation Strong cash position and no debt; allocating capital to Catalyst, new compensation plan, and Trilivy rollout. Cash and investments $169M; Catalyst program launched Q2 to drive facility rationalization and AI efficiencies; enhanced compensation plan launched Aug 1; ongoing investment in Metabolic Health Institute and product development. ### Milestones - **Trilivy brand launch** [new]: Launched in July as the primary consumer brand replacing OPTAVIA, with rollout of Reset Fuelings planned over coming quarters. - **Metabolic Health Institute** [new]: July launch to advance research, product development and education, backed by scientific advisory board. - **Catalyst program** [on_track]: Started Q2 to generate millions of cost savings through facility rationalization and AI; impact expected in Q3. - **Enhanced compensation plan** [new]: Introduced Aug 1 to sharpen focus on developing Executive Directors and drive sustainable growth. - **Reset Fuelings pilot** [delivered]: Spring pilot with employees, coaches and clients showed overwhelmingly positive feedback; full rollout later this month. - **Coach convention** [delivered]: Sold‑out July event used to promote Trilivy, compensation plan and Coach Hub training platform. - **3.0 strategy implementation** [on_track]: Ongoing focus on speed, simplicity, scale and stewardship to return to profitability by Q4 2026. - **Trilivy Coach Hub training platform** [new]: Introduced at July convention to standardize coach training on the new brand. ### Fears / risks - **Coach count decline**: Active earning coaches fell 48.7% YoY to 11,700, pressuring revenue volume. - **GLP-1 competition**: Rapid adoption of GLP‑1 medications is reducing the number of traditional weight‑loss coaches. - **Catalyst savings uncertainty**: Management cannot yet quantify the magnitude of cost savings from the Catalyst program. - **Margin pressure**: Loss of leverage on fixed costs reduced gross margin to 69.9% and increased SG&A as a revenue percent. - **Product rollout risk**: While early feedback is positive, any delays in scaling Trilivy Fuelings could affect future margins. - **Revenue volatility**: Q2 revenue down 27.6% YoY due to lower coach volume despite productivity gains. - **Operating loss**: Loss from operations widened to $4.3M, a $3.3M increase YoY. - **Tax valuation allowance**: Full valuation allowance on deferred tax assets resulted in a negative effective tax rate. ### Key quotes > “In our second quarter, we continued to see positive indicators in our business, maintaining a trend that began in late 2025.” > “We anticipate that these positive trends will continue through the remainder of the year, supported by the launch of our new consumer brand, Trilivy.” > “We've seen no major hiccups with respect to that change in the evolution of the brand.” ## Quarter one-liners - **2026 Q2:** Medifast reports Q2 revenue in line with guidance, coach productivity up but active coach count down sharply, and highlights new Trilivy brand and Catalyst cost‑savings program as paths to Q4 profitability. - **2026 Q1:** — - **2025 Q4:** Medifast Q4 revenue $75.1M (-37% YoY); coach productivity turns positive for first time since 2022; guides 2026 revenue $270-300M with profitability improvement expected Q4 after new product launch. - **2025 Q3:** Medifast Q3 revenue $89.4M at high end, coach productivity -2% YoY, pivoting to metabolic health with new clinical data and product line, guiding Q4 $65-80M revenue and $0.70-1.25 loss. - **2025 Q2:** Medifast Q2 revenue $105.6M (-37% YoY), coaches down 33% to 22.8K; launched Premier+ pricing and EDGE coach program; guides Q3 revenue $70-90M, EPS $0 to -$0.60; pivoting to metabolic health amid GLP-1 disruption. - **2025 Q1:** Medifast Q1 rev $115.7M (-33.8%), EPS -$0.07; coaches -32.8% to 25.4K but new cohorts improve productivity; Q2 guide $85-105M rev, loss $0-$0.55; coach-led turnaround amid GLP-1 shift. - **2024 Q4:** Medifast reports Q4 revenue down 38% but beat EPS guidance, highlights new ASCEND line, cost savings, and ongoing coach productivity pressure amid growing GLP‑1 market. - **2024 Q3:** — ## Theme arcs - **Revenue trend** (deteriorating): Revenue fell 38% YoY in Q4 2024 and continued to decline, with guidance indicating further drops through 2026. - **Coach attrition** (deteriorating): Active earning coaches dropped 34% YoY in Q4 2024 and over 40% by Q4 2025, though Q4 2026 shows first positive productivity. - **Margin pressure** (deteriorating): Gross margin slipped as fixed‑cost leverage eroded, falling to 69.9% in Q2 2026. - **Cost‑reduction initiatives** (improving): Programs like Fuel for the Future, restructuring savings, and Catalyst are delivering cost cuts. - **Product launch pipeline** (new): ASCEND (2024), ACTIVE (2025), Premier+ pricing, EDGE program, and 2026 metabolic‑health products including Trilivy. - **GLP‑1 disruption impact** (deteriorating): Repeatedly cited as a threat to traditional weight‑loss demand and coach base. - **Capital strength** (stable): Cash balances above $160 M with zero debt across all periods. ## Fear persistence - **Coach attrition** [recurring]: Active earning coaches declined sharply each quarter, noted from Q4 2024 through Q4 2026. - **GLP‑1 disruption** [recurring]: Repeatedly cited as eroding traditional weight‑loss demand and coach base. - **Revenue contraction** [recurring]: Consistent revenue declines highlighted in every call after Q4 2024. - **Marketing efficiency** [recurring]: Company‑led marketing cost pressures noted in Q4 2024 and Q4 2025. ## Guidance path 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/MED`